Matthew Call joins Iteos as COO

Iteos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, last week announced the appointment of Matthew Call as its Chief Operating Officer. Matthew will also be responsible for business development.

ADVERTISEMENT

Matthew joins iTeos with 20 years of experience in operational leadership and business development roles, most recently serving as Chief Operating Officer at Endocyte, which was acquired by Novartis for $2.1 billion in 2018. During his 16 year tenure at Endocyte, he had responsibility for all business development and strategic transactions and led a variety of functions including new product planning, marketing and project management.

“I am delighted to join iTeos at such an exciting time as the company advances its key growth initiatives. Our talented staff, highly differentiated pipeline programs, and strong investor base positions iTeos well to transform the treatment paradigm for people living with cancer,” said Matthew Call.

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!